Sulfation modulates the targeting properties of hyaluronic acid to P-selectin and CD44.
CD44
P-selectin
dual target
hyaluronic acid
near infrared
Journal
ACS biomaterials science & engineering
ISSN: 2373-9878
Titre abrégé: ACS Biomater Sci Eng
Pays: United States
ID NLM: 101654670
Informations de publication
Date de publication:
08 06 2020
08 06 2020
Historique:
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
4
7
2020
Statut:
ppublish
Résumé
Many targeting strategies can be employed to direct nanoparticles to tumors for imaging and therapy. However, tumors display a dynamic, heterogeneous microenvironment that undergoes spatiotemporal changes, including the expression of targetable cell-surface biomarkers. Here, we develop a nanoparticle system to effectively target two receptors overexpressed in the microenvironment of aggressive tumors. Hyaluronic acid (HA) was regioselectivity modified using a multi-step synthetic approach to alter binding specificities for CD44 and P-selectin to tumor cell interaction. The dual-targeting strategy utilizes sulfate modifications on HA that targets P-selectin, in addition to native targeting of CD44, which exploits spatiotemporal alterations in the expression patterns of these two receptors in cancer sites. Using biophysical characterization and
Identifiants
pubmed: 32617404
doi: 10.1021/acsbiomaterials.0c00115
pmc: PMC7331950
mid: NIHMS1592040
doi:
Substances chimiques
P-Selectin
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
3585-3598Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103427
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA036727
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM106397
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB019449
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Adv Drug Deliv Rev. 2017 Jan 1;108:51-67
pubmed: 26806856
Small. 2015 Mar;11(9-10):1055-71
pubmed: 25387905
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
J Pharm Sci. 2000 Nov;89(11):1452-64
pubmed: 11015690
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W270-7
pubmed: 21624888
Int J Nanomedicine. 2017 Nov 28;12:8483-8493
pubmed: 29238188
Clin Cancer Res. 2009 Jul 15;15(14):4722-32
pubmed: 19584158
Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5480-5
pubmed: 23509259
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Nat Struct Mol Biol. 2007 Mar;14(3):234-9
pubmed: 17293874
Biochem Pharmacol. 2006 Aug 14;72(4):474-85
pubmed: 16780802
Cancer Res. 1997 Mar 15;57(6):1206-12
pubmed: 9067294
Molecules. 2017 Aug 23;22(9):
pubmed: 28832535
Bioconjug Chem. 2015 Feb 18;26(2):294-303
pubmed: 25565445
Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
Elife. 2017 Oct 04;6:
pubmed: 28976305
Theranostics. 2016 Oct 1;6(13):2314-2328
pubmed: 27877237
ACS Appl Mater Interfaces. 2018 Mar 7;10(9):7697-7703
pubmed: 29457709
J Control Release. 2016 Dec 10;243:303-322
pubmed: 27794493
Int J Nanomedicine. 2017 Jul 28;12:5421-5431
pubmed: 28814860
Chem Sci. 2018 Nov 1;10(3):866-878
pubmed: 30774881
Pharmaceuticals (Basel). 2018 Apr 09;11(2):
pubmed: 29642542
Sci Transl Med. 2016 Jun 29;8(345):345fs11
pubmed: 27358495
Biochim Biophys Acta. 2009 Feb;1790(2):141-6
pubmed: 19026722
Nat Commun. 2013;4:1673
pubmed: 23575677
J Mater Chem B. 2017;5(41):8183-8192
pubmed: 29354263
J Clin Oncol. 2005 Feb 20;23(6):1152-60
pubmed: 15718311
Adv Drug Deliv Rev. 2017 Jan 1;108:25-38
pubmed: 27137110
Angew Chem Int Ed Engl. 2015 Dec 1;54(49):14626-37
pubmed: 26471238
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Adv Pharm Bull. 2017 Apr;7(1):3-9
pubmed: 28507932
Adv Drug Deliv Rev. 2013 Oct;65(10):1284-98
pubmed: 24018362
Mol Biosyst. 2012 Feb;8(2):543-7
pubmed: 22159602
J Phys Chem B. 2013 Dec 27;117(51):16443-54
pubmed: 24304345
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul;12(4):e1624
pubmed: 32162485
Acta Biomater. 2018 Jul 15;75:323-333
pubmed: 29890268
ACS Nano. 2015 Aug 25;9(8):8012-21
pubmed: 26203676
Biomaterials. 2016 Jan;77:130-138
pubmed: 26588795
Sci Transl Med. 2016 Jun 29;8(345):345ra87
pubmed: 27358497
Nat Commun. 2017 Feb 13;8:14292
pubmed: 28194032
Immunotherapy. 2016 Jul;8(8):941-58
pubmed: 27381686
Biomacromolecules. 2011 Jul 11;12(7):2502-11
pubmed: 21598905
Prikl Biokhim Mikrobiol. 2010 May-Jun;46(3):291-8
pubmed: 20586281
J Control Release. 2015 Dec 10;219:576-595
pubmed: 26435455
Acta Biomater. 2018 Dec;82:158-170
pubmed: 30342282
Cell. 2000 Oct 27;103(3):467-79
pubmed: 11081633
Stem Cells Transl Med. 2015 Sep;4(9):1033-43
pubmed: 26136504
Nanoscale. 2016 Mar 28;8(12):6801-9
pubmed: 26957191